Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report

Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is considerably more frequent in squamous cell lung cancer (SqCLC) than in other subtypes of lung cancer and may be a promising target for this histology. Here, we present the course of diagnosis and treatment of a patient with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dias e Silva, Douglas, Borba, Guilherme Bes, Beal, Juliana Rodrigues, Botrus, Gehan, Osawa, Akemi, Araújo, Sérgio Eduardo Alonso, Moura, Fernando, Guendelmann, Rafael Aliosha Kaliks, Uson Junior, Pedro Luiz Serrano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963198/
https://www.ncbi.nlm.nih.gov/pubmed/36835617
http://dx.doi.org/10.3390/ijms24044209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963198/
https://www.ncbi.nlm.nih.gov/pubmed/36835617
http://dx.doi.org/10.3390/ijms24044209

Ejemplares similares